4.8 Article

Glycosylase base editors enable C-to-A and C-to-G base changes

Journal

NATURE BIOTECHNOLOGY
Volume 39, Issue 1, Pages 35-40

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41587-020-0592-2

Keywords

-

Funding

  1. National Key Research and Development Program of China [2019YFA0904900]
  2. Key Research Program of the Chinese Academy of Science [KFZD-SW-215]
  3. National Natural Science Foundation of China [31861143019]
  4. Newton Fund PhD placement program grant under the UK-China Joint Research and Innovation Partnership Fund [352639434]
  5. Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project [TSBICIP-PTJS-003]

Ask authors/readers for more resources

The study introduces novel glycosylase base editors (GBEs) that can induce C-to-A and C-to-G transversions in Escherichia coli and mammalian cells, respectively. The new editors exhibit high editing specificity and efficiency, making them potential tools for targeting G/C disease-causing mutations.
Current base editors (BEs) catalyze only base transitions (C to T and A to G) and cannot produce base transversions. Here we present BEs that cause C-to-A transversions in Escherichia coli and C-to-G transversions in mammalian cells. These glycosylase base editors (GBEs) consist of a Cas9 nickase, a cytidine deaminase and a uracil-DNA glycosylase (Ung). Ung excises the U base created by the deaminase, forming an apurinic/apyrimidinic (AP) site that initiates the DNA repair process. In E. coli, we used activation-induced cytidine deaminase (AID) to construct AID-nCas9-Ung and found that it converts C to A with an average editing specificity of 93.8% +/- 4.8% and editing efficiency of 87.2% +/- 6.9%. For use in mammalian cells, we replaced AID with rat APOBEC1 (APOBEC-nCas9-Ung). We tested APOBEC-nCas9-Ung at 30 endogenous sites, and we observed C-to-G conversions with a high editing specificity at the sixth position of the protospacer between 29.7% and 92.2% and an editing efficiency between 5.3% and 53.0%. APOBEC-nCas9-Ung supplements the current adenine and cytidine BEs (ABE and CBE, respectively) and could be used to target G/C disease-causing mutations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available